GlycoEra AG raises $130 million in a Series B funding round led by Novo Holdings to advance its novel IgG4-targeted protein degrader program for autoimmune diseases.

May 27, 2025•2 months ago

Amount Raised

$130 Million

Round Type

series b

WädenswilBiotechnology

Investors

Sixty Degree CapitalMp Healthcare Venture ManagementAgent CapitalBristol Myers SquibbRoche Ventures5 Am VenturesSofinnova PartnersQiaLife Arc VenturesCatalio Capital ManagementNovo Holdings

Description

GlycoEra AG has announced the closing of a $130 million Series B financing. The funding will support the development of its lead IgG4-targeted protein degrader and further advance its precision immunology pipeline. The round was led by Novo Holdings, with participation from several significant investors. The company aims to initiate first-in-human clinical trials later this year.

Company Information

Company

GlycoEra AG

Location

Wädenswil, Zurich, Switzerland

About

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends